Tyson Foods, Inc. vs Twist Bioscience Corp — how do they compare? Tyson Foods, Inc. trades at $52.15 (market cap $18.39B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Tyson Foods, Inc. is far larger — about 2.2× Twist Bioscience Corp's market cap, and Tyson Foods, Inc. pays a 3.9% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TSN | TWST | |
|---|---|---|
Market Cap | $18.39B | $8.42B |
Sector | Consumer Staples | Health |
52-Week High | $68.75 | $153.10 |
52-Week Low | $50.72 | $24.16 |
Enterprise Value | $25.66B | $8.35B |
Dividend Yield | 3.9% | — |
Signals from Pluang's Aura AI — not financial advice
Tyson Foods (TSN) trades at $52.28, up 1.67% today, but faces bearish technical signals with the stock trading near key support levels. The company reported mixed quarterly results with two beats and one miss in recent quarters, while maintaining modest profitability with 1.03% net margins. Recent news highlights ongoing fraud investigations and reduced 2026 revenue guidance due to beef segment pressures, creating investor uncertainty despite continued institutional buying interest.
The outlook remains cautious with Wall Street maintaining a $69 price target but technical indicators signaling bearish momentum. Investment opportunity exists in the discounted valuation (P/S 0.33) if operational improvements materialize, though risks include ongoing legal scrutiny, commodity price volatility, and execution challenges in the beef business that could pressure near-term performance.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Trailing returns across standard periods
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →